This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/drugbank/drug/DB04573/identifier/drugbank/
n14http://linked.opendata.cz/resource/mesh/concept/
n10http://linked.opendata.cz/resource/drugbank/company/
n12http://bio2rdf.org/drugbank:
n7http://linked.opendata.cz/resource/drugbank/drug/DB04573/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/drug/DB04573/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB04573/identifier/pharmgkb/
n16http://linked.opendata.cz/resource/drugbank/drug/DB04573/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n22http://linked.opendata.cz/resource/drugbank/drug/DB04573/identifier/pdb/
n24http://linked.opendata.cz/resource/drugbank/drug/DB04573/identifier/kegg-compound/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB04573/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/resource/drugbank/drug/DB04573/identifier/pubchem-substance/
n21http://linked.opendata.cz/resource/drugbank/drug/DB04573/identifier/kegg-drug/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB04573
rdf:type
n5:Drug
n5:description
A hydroxylated metabolite of estradiol or estrone that has a hydroxyl group at C3-beta, 16-alpha, and 17-beta position. Estriol is a major urinary estrogen. During pregnancy, large amount of estriol is produced by the placenta. Isomers with inversion of the hydroxyl group or groups are called epiestriol. Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada. It is however available in the United States by prescription filled only by compounding pharmacies. It has also been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes.
n5:generalReferences
# Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR: Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol. 2003 Dec 1;171(11):6267-74. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14634144 # "Trimesta":http://www.syntheticbiologics.com/trimesta
n5:group
approved
n5:indication
Used as a test to determine the general health of an unborn fetus.
owl:sameAs
n12:DB04573 n17:DB04573
dcterms:title
Estriol
adms:identifier
n4:27974 n7:5553 n15:PA164769104 n16:Estriol n19:5756 n20:46505881 n21:D00185 n22:ESL n23:DB04573 n24:C05141
n5:mechanismOfAction
Estriol levels can be measured to give an indication of the general health of the fetus. DHEA-S is produced by the adrenal cortex of the fetus. This is converted to estriol by the placenta. If levels of "unconjugated estriol" are abnormally low in a pregnant woman, this may indicate a problem with the development of the child. The drug interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estriol upon the target cell. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.
n5:packager
n10:271B3F9F-363D-11E5-9242-09173F13E4C5 n10:271B3FA0-363D-11E5-9242-09173F13E4C5
n5:synonym
(16α,17β)-estra-1,3,5(10)-triene-3,16,17-triol 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol Estriol Deuslon-a Trihydroxyestrin 16α-hydroxyestradiol 3,16alpha,17beta-Trihydroxy-delta(1,3,5)-estratriene (16alpha,17beta)-Estra-1,3,5(10)-triene-3,16,17-triol 16alpha-hydroxyestradiol Estriel Oestriol 16-alpha-Hydroxyestradiol
n5:toxicity
ORAL (LD50): Acute: >2000 mg/kg [Rat].
n5:salt
n5:synthesisReference
James V. Freeman, Gary M. Johnson, "Synthesis of 6.alpha.-functionalized estriol haptens and protein conjugates thereof." U.S. Patent US5902888, issued June, 1973.
n13:hasConcept
n14:M0007788
n5:IUPAC-Name
n6:271B3FA5-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B3FAB-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B3FAA-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B3FA7-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B3FA8-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B3FA9-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B3FA3-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B3FA1-363D-11E5-9242-09173F13E4C5 n6:271B3FA4-363D-11E5-9242-09173F13E4C5 n6:271B3FBC-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B3FA2-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:G03CC06 n9:G03CA04
n5:H-Bond-Acceptor-Count
n6:271B3FB1-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B3FB2-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B3FAC-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B3FAD-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B3FAF-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B3FAE-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B3FB0-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
50-27-1
n5:Bioavailability
n6:271B3FB7-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B3FB9-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B3FBA-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B3FBB-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B3FB6-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B3FB5-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B3FB8-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B3FA6-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B3FB3-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B3FB4-363D-11E5-9242-09173F13E4C5